Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma (Nasdaq: ZEAL) announced its participation at the 81st Annual American Diabetes Association Scientific Sessions, presenting six abstracts on Zegalogue® (dasiglucagon) from June 25-29, 2021. This includes one oral presentation demonstrating dasiglucagon's efficacy in treating severe hypoglycemia in diabetes patients aged six and above, following its FDA approval on March 22, 2021. The company aims to advance treatment options for those affected by severe hypoglycemia, showcasing its commitment to diabetes care.
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions in its shares by persons in managerial roles and their associates, as per corporate governance guidelines. The company focuses on innovative peptide-based medicines, with a pipeline featuring three late-stage drug candidates. Zealand's notable products include V-Go® and Zegalogue®. The press release emphasizes the company's commitment to enhancing patient care through peptide therapeutics, supported by collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.
On June 10, 2021, Zealand Pharma announced a capital increase of DKK 89,996 by issuing 89,996 new shares due to the exercise of employee warrants. The exercise price was DKK 135.30 for 4,395 shares and DKK 100.80 for 85,601 shares, resulting in total proceeds of DKK 9,223,224.30. The new shares will be listed on Nasdaq Copenhagen, raising the share capital to DKK 43,541,838. This move is part of Zealand Pharma's employee incentive programs, providing shares with voting rights at general meetings.
Zealand Pharma (Nasdaq: ZEAL) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. Members of the senior management team are scheduled to present virtually at 9:40 a.m. ET / 3:40 p.m. CET. A live webcast will be available on the Company's website under 'Events & Presentations,' with an archived replay following the event. Zealand focuses on peptide-based medicines and has a strong pipeline, including the recently approved Zegalogue for severe hypoglycemia in diabetes patients.
Boehringer Ingelheim and Zealand Pharma (Nasdaq: ZEAL) announced that the FDA granted Fast Track Designation for their investigational GLP-1/glucagon dual agonist, BI 456906, aimed at treating non-alcoholic steatohepatitis (NASH). This designation highlights the significant unmet medical need affecting an estimated 444 million adults globally. The dual agonist is currently in a Phase II trial assessing its efficacy in adults with NASH and liver fibrosis. The collaboration aims to leverage both companies' strengths in developing innovative therapies for cardiometabolic diseases.
Zealand Pharma (NASDAQ: ZEAL) announced its total number of shares and voting rights as of May 31, 2021, following the exercise of employee warrants. The total number of shares stands at 43,451,842, with a corresponding share capital of 43,451,842 DKK. This update is part of a compliance requirement under the Danish Capital Markets Act. Zealand continues to focus on innovative peptide-based medicines, with a pipeline that includes several candidates in late-stage development and ongoing collaborations with major pharmaceutical partners.
Zealand Pharma (Nasdaq: ZEAL) announced transactions involving its shares by managerial personnel and their close associates. This disclosure is part of the company's regulatory requirements. The company focuses on developing peptide-based medicines, with more than 10 drug candidates in clinical development, including the recently FDA-approved Zegalogue for severe hypoglycemia. Zealand's pipeline also includes several late-stage candidates and collaborations with major pharmaceutical companies.
Zealand Pharma has launched a new long-term incentive program (LTIP) for its US-based corporate management, aligning with their remuneration policy. The program includes 32,363 restricted stock units (RSUs) and 97,090 performance stock units (PSUs), aimed at enhancing performance and retaining top talent. The RSUs vest annually over three years, while the PSUs vest based on operational and market-based performance goals. The estimated value of the share-based remuneration is DKK 24.8 million, with no dilution effect on shareholders due to the use of treasury shares.
Zealand Pharma will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. Senior management will present insights into the company's innovative peptide-based medicines, aiming to transform patient lives. The event will be accessible via a live webcast on Zealand's investor relations page, with a replay available shortly after. Zealand Pharma is focused on developing treatments for diabetes, including V-Go® and Zegalogue®, showcasing a strong pipeline with multiple candidates in clinical stages.
Zealand Pharma announced an increase in share capital by DKK 2,000 through the exercise of employee warrants on May 20, 2021. This resulted in the issuance of 2,000 new shares at an exercise price of DKK 135.30 each, aggregating total proceeds of DKK 270,600. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority, bringing the total nominal share capital to DKK 43,451,842, divided into the same number of shares. Each new share carries voting rights and dividends from the exercise date.
